TFFP Insider Trading
Notice: This stock is marked as potentially delisted. It may not be actively trading.
Insider Ownership Percentage: 4.50%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00
TFF Pharmaceuticals Share Price & Price History
Current Price: $0.07
Price Change: +0.30 (1.20%)
As of 04/10/2025 01:00 AM ET
TFF Pharmaceuticals Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 8/15/2023 | Carlson Capital L P | Major Shareholder | Sell | 8,600 | $11.00 | $94,600.00 | 202,600 |  |
| 8/15/2023 | Harlan F Weisman | CEO | Buy | 24,000 | $6.25 | $150,000.00 | 32,584 | |
| 8/15/2023 | Stephen Rocamboli | Director | Buy | 800 | $6.25 | $5,000.00 | 1,440 | |
| 8/15/2023 | Zamaneh Mikhak | Insider | Buy | 4,800 | $6.25 | $30,000.00 | 5,400 | |
| 3/10/2023 | Harlan F Weisman | CEO | Buy | 6,000 | $22.00 | $132,000.00 | 8,584 | |
| 3/10/2023 | Kirk Allen Coleman | CFO | Buy | 480 | $19.75 | $9,480.00 | 627 | |
| 3/10/2023 | Zamaneh Mikhak | Insider | Buy | 600 | $20.50 | $12,300.00 | 600 | |
| 12/15/2022 | Harlan F Weisman | CEO | Buy | 2,000 | $26.50 | $53,000.00 | 2,584 | |
TFF Pharmaceuticals Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 8/15/2024 | Armistice Capital LLC | 185,695 | $0.31M | 0.0% | N/A | 5.990% |  |
| 7/17/2024 | Westside Investment Management Inc. | 50,491 | $84K | 0.0% | +28.7% | 1.629% | |
| 4/19/2024 | Westside Investment Management Inc. | 39,225 | $0.24M | 0.1% | +382.1% | 1.557% | |
| 2/12/2024 | AIGH Capital Management LLC | 29,482 | $0.21M | 0.1% | -98.9% | 1.247% | |
| 1/12/2024 | Westside Investment Management Inc. | 8,136 | $57K | 0.0% | -81.3% | 0.343% | |
| 1/1/2024 | Vanguard Group Inc. | 846,884 | $0.30M | 0.0% | -0.8% | 35.734% | |
| 11/15/2023 | Worth Venture Partners LLC | 646,832 | $0.23M | 0.1% | +66.2% | 1.153% | |
| 11/13/2023 | AIGH Capital Management LLC | 2,655,235 | $0.93M | 0.4% | +70.7% | 4.734% | |
| 8/8/2023 | Gagnon Securities LLC | 161,074 | $76K | 0.0% | -27.2% | 0.463% | |
| 5/8/2023 | Sigma Planning Corp | 155,191 | $0.11M | 0.0% | +53.8% | 0.446% | |
| 4/10/2023 | Gagnon Securities LLC | 221,207 | $0.15M | 0.0% | +255.3% | 0.636% | |
| 2/16/2023 | AIGH Capital Management LLC | 1,739,130 | $1.83M | 0.6% | N/A | 4.998% | |
| 2/3/2023 | Sepio Capital LP | 330,600 | $0.35M | 0.0% | +4.9% | 0.950% | |
| 1/31/2023 | Princeton Capital Management LLC | 101,449 | $0.11M | 0.0% | -25.7% | 0.292% | |
| 1/24/2023 | Sigma Planning Corp | 100,891 | $0.11M | 0.0% | +31.2% | 0.290% | |
| 11/15/2022 | Carlson Capital L P | 275,000 | $1.12M | 0.1% | -8.3% | 1.079% | |
| 11/7/2022 | Virtu Financial LLC | 20,776 | $84K | 0.0% | N/A | 0.082% | |
| 10/28/2022 | Sepio Capital LP | 315,060 | $1.28M | 0.1% | +222.5% | 1.237% | |
| 8/17/2022 | Quantum Private Wealth LLC | 11,082 | $62K | 0.0% | N/A | 0.044% | |
| 8/9/2022 | Fermata Advisors LLC | 27,599 | $0.16M | 0.1% | +15.7% | 0.109% | |
| 8/1/2022 | Gagnon Securities LLC | 284,361 | $1.61M | 0.3% | +12.4% | 1.121% | |
| 7/28/2022 | Selective Wealth Management Inc. | 5,000 | $28K | 0.0% | +100.0% | 0.020% | |
| 7/26/2022 | Sepio Capital LP | 97,700 | $0.55M | 0.1% | N/A | 0.385% | |
| 7/15/2022 | Westside Investment Management Inc. | 51,650 | $0.29M | 0.0% | +11.8% | 0.204% | |
| 5/11/2022 | GSA Capital Partners LLP | 105,388 | $0.67M | 0.1% | -18.5% | 0.415% | |
| 4/25/2022 | Westside Investment Management Inc. | 46,200 | $0.29M | 0.0% | +133.6% | 0.182% | |
| 2/15/2022 | Westside Investment Management Inc. | 19,775 | $0.18M | 0.0% | N/A | 0.078% | |
| 2/14/2022 | PDT Partners LLC | 27,083 | $0.24M | 0.0% | -18.7% | 0.107% | |
| 2/14/2022 | GSA Capital Partners LLP | 129,241 | $1.15M | 0.1% | -11.0% | 0.509% | |
| 2/9/2022 | Princeton Capital Management LLC | 125,771 | $1.12M | 0.3% | -1.8% | 0.496% | |
| 2/8/2022 | Gagnon Securities LLC | 252,473 | $2.24M | 0.3% | -10.5% | 0.995% | |
| 2/4/2022 | IndexIQ Advisors LLC | 31,121 | $0.28M | 0.0% | -6.1% | 0.123% | |
| 2/2/2022 | Fermata Advisors LLC | 22,435 | $0.20M | 0.1% | +9.1% | 0.088% | |
| 1/28/2022 | National Asset Management Inc. | 31,800 | $0.28M | 0.0% | +18.7% | 0.125% | |
| 1/27/2022 | Janney Montgomery Scott LLC | 259,009 | $2.30M | 0.0% | +32.4% | 1.021% | |
| 1/20/2022 | Parallel Advisors LLC | 2,963 | $26K | 0.0% | N/A | 0.012% | |
| 1/19/2022 | Newbridge Financial Services Group Inc. | 4,000 | $35K | 0.0% | N/A | 0.016% | |
| 11/16/2021 | National Asset Management Inc. | 26,800 | $0.21M | 0.0% | N/A | 0.106% | |
| 11/15/2021 | Marshall Wace LLP | 11,951 | $92K | 0.0% | N/A | 0.047% | |
| 11/15/2021 | GSA Capital Partners LLP | 145,295 | $1.12M | 0.1% | +88.0% | 0.573% | |
| 11/12/2021 | Renaissance Technologies LLC | 87,000 | $0.67M | 0.0% | -52.4% | 0.343% | |
| 11/12/2021 | Carlson Capital L P | 227,701 | $1.76M | 0.1% | +5.9% | 0.897% | |
| 11/12/2021 | Apis Capital Advisors LLC | 80,000 | $0.62M | 0.6% | -52.9% | 0.315% | |
| 11/12/2021 | Gagnon Securities LLC | 282,229 | $2.18M | 0.3% | -38.5% | 1.112% | |
| 11/12/2021 | MYDA Advisors LLC | 40,000 | $0.31M | 0.1% | N/A | 0.158% | |
| 11/12/2021 | Geode Capital Management LLC | 124,701 | $0.96M | 0.0% | +2.0% | 0.491% | |
| 11/10/2021 | IndexIQ Advisors LLC | 33,132 | $0.26M | 0.0% | +11.1% | 0.131% | |
| 11/9/2021 | BlackRock Inc. | 259,270 | $2M | 0.0% | -0.9% | 1.022% | |
| 11/2/2021 | Raymond James & Associates | 36,800 | $0.28M | 0.0% | +65.2% | 0.145% | |
| 10/29/2021 | Janney Montgomery Scott LLC | 195,656 | $1.51M | 0.0% | +22.7% | 0.771% | |
| 10/28/2021 | Sigma Planning Corp | 75,900 | $0.59M | 0.0% | +5.5% | 0.299% | |
| 10/19/2021 | Assenagon Asset Management S.A. | 22,515 | $0.17M | 0.0% | -45.5% | 0.089% | |
| 8/17/2021 | Millennium Management LLC | 113,264 | $1.09M | 0.0% | -52.7% | 0.447% | |
| 8/16/2021 | State Street Corp | 43,878 | $0.42M | 0.0% | N/A | 0.173% | |
Data available starting January 2016
TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment and prophylaxis of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It also develops other dry powder products, such as Augmenta human derived monoclonal antibodies for the treatment of COVID-19 disease; and other vaccines. It has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs. TFF Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Fort Worth, Texas.
Read More on TFF Pharmaceuticals
Volume
N/A
Average Volume
N/A
Market Capitalization
$288.60 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
